Short Interest in Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Drops By 55.4%

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) was the recipient of a large decline in short interest during the month of August. As of August 14th, there was short interest totaling 56,253 shares, a decline of 55.4% from the July 30th total of 126,080 shares. Currently, 2.5% of the company’s shares are sold short. Based on an average daily volume of 140,397 shares, the days-to-cover ratio is presently 0.4 days.

Analyst Ratings Changes

A number of brokerages recently issued reports on LABT. Wall Street Zen downgraded Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Weiss Ratings started coverage on shares of Lakewood-Amedex Biotherapeutics in a research note on Monday, July 20th. They set a “sell (e-)” rating for the company. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Lakewood-Amedex Biotherapeutics Stock Down 7.6%

NASDAQ:LABT traded down $0.19 during mid-day trading on Friday, hitting $2.30. 95,736 shares of the company’s stock traded hands, compared to its average volume of 145,485. The stock has a fifty day moving average of $2.54. Lakewood-Amedex Biotherapeutics has a twelve month low of $1.66 and a twelve month high of $98.20. The company has a market cap of $5.45 million and a P/E ratio of -0.48.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last issued its quarterly earnings results on Friday, August 14th. The company reported ($2.75) earnings per share for the quarter. Analysts expect that Lakewood-Amedex Biotherapeutics will post 2.52 earnings per share for the current year.

About Lakewood-Amedex Biotherapeutics

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.